A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 459,300 shares of RVNC stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
459,300
Previous 572,000 19.7%
Holding current value
$1.18 Million
Previous $1.47 Million 19.73%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.57 - $2.57 $289,639 - $289,639
-112,700 Reduced 19.7%
459,300 $1.18 Million
Q2 2024

Aug 09, 2024

BUY
$2.34 - $4.73 $464,022 - $937,959
198,300 Added 53.06%
572,000 $1.47 Million
Q1 2024

May 13, 2024

BUY
$4.65 - $9.31 $1.74 Million - $3.48 Million
373,700 New
373,700 $1.84 Million
Q3 2023

Nov 14, 2023

SELL
$11.47 - $25.07 $367,234 - $802,666
-32,017 Reduced 15.21%
178,500 $2.05 Million
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $5.2 Million - $7.92 Million
210,517 New
210,517 $5.33 Million
Q2 2020

Aug 13, 2020

SELL
$12.6 - $26.55 $5.96 Million - $12.6 Million
-472,700 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$12.46 - $27.81 $2.55 Million - $5.69 Million
-204,773 Reduced 30.23%
472,700 $7 Million
Q4 2019

Feb 13, 2020

SELL
$11.66 - $20.15 $2.32 Million - $4.01 Million
-198,900 Reduced 22.7%
677,473 $11 Million
Q3 2019

Nov 13, 2019

SELL
$10.22 - $14.5 $4.65 Million - $6.59 Million
-454,600 Reduced 34.16%
876,373 $11.4 Million
Q2 2019

Aug 12, 2019

BUY
$10.67 - $15.49 $4.58 Million - $6.64 Million
428,900 Added 47.55%
1,330,973 $17.3 Million
Q1 2019

May 14, 2019

BUY
$15.4 - $20.39 $5.09 Million - $6.73 Million
330,200 Added 57.74%
902,073 $14.2 Million
Q4 2018

Feb 13, 2019

BUY
$18.06 - $24.96 $10.3 Million - $14.3 Million
571,873 New
571,873 $11.5 Million

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.